Novartis on Tuesday (Jul 18) raised its full-year earnings guidance on strong drug sales, and mapped out the planned spinoff and stock market debut of its generic medicines division Sandoz for early in the fourth quarter.

The Swiss drugmaker said in a statement it expected group core operating income to grow by a low double-digit percentage in 2023, up from high single-digit growth previously projected.

Novartis shareholders will vote on the proposed Sandoz spinoff and complete separation at an extraordinary general meeting on Sep 15.

A listing on the SIX Swiss Exchange, combined with an American Depositary Receipt programme in the United States, would follow early in the fourth quarter, the company added.

The separate listing was previously projected to happen during the second half.

The Swiss pharma major is also initiating a previously flagged share buyback programme worth up to US$15 billion to be completed by year-end 2025, following the completion of its previous share buyback in June 2023. REUTERS

GET BT IN YOUR INBOX DAILY

Start and end each day with the latest news stories and analyses delivered straight to your inbox.

Sign UpVIEW ALL